clinical trial · NCT07450378
QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
Qilu Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 120
Heterozygous Familial Hypercholesterolemia (HeFH)QLC7401 InjectionPlacebo
brief summary
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.
started
May 1, 2026
primary completion
Apr 1, 2028
completion
Jul 1, 2028
last updated
Mar 4, 2026
official title
Evaluation of Efficacy and Safety of QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia on a Stable Lipid-lowering Therapy: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol